Back to results
US 2009/0155899 A1Published application
Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsNicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
Life of this patent
Estimating the term…
Abstract
Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
Claims9
An isolated nucleic acid molecule encoding a fusion protein consisting of:
- (a) a vascular endothelial growth factor (VEGF) receptor component having immunoglobulin-like (Ig) domains consisting of an Ig domain 2 of a first VEGF receptor human Flt1 and an Ig domain 3 of a second VEGF receptor human Flt4;
- and (b) a multimerizing component.
Dependencies are inferred from the claim text.